Holen Sie sich die Stockscreener-App
144.94
1.61%
2.29
Vorhandelsmarkt:
145.55
0.61
+0.42%
Schlusskurs vom Vortag:
$142.65
Offen:
$142.11
24-Stunden-Volumen:
2.08M
Relative Volume:
1.66
Marktkapitalisierung:
$10.04B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$302.80M
KGV:
33.73
EPS:
4.2965
Netto-Cashflow:
$387.80M
1W Leistung:
-6.41%
1M Leistung:
-9.42%
6M Leistung:
-55.70%
1J Leistung:
-55.24%
1-Tages-Spanne:
$141.65
$145.13
1-Wochen-Bereich:
$140.63
$156.50
52-Wochen-Spanne:
$140.63
$354.88
Insulet Corp Stock (PODD) Company Profile
Firmenname
Insulet Corp
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
144.94 | 9.88B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-04-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corp Aktie (PODD) Neueste Nachrichten
Insulet Device Correction Puts Omnipod Safety And Valuation In Focus - Yahoo Finance
TRADE SECRETS—Fed. Cir.: Medical device company’s $59.4 million judgment and injunction against South Korean competitor reversed - VitalLaw.com
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Eoflow: Stayin' Alive [U.S. Court of Appeals Overturns $59.4 Mn Trade Secret Verdict Vs Insulet] - Smartkarma
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Millions of Omnipods recalled due to manufacturing issue that may lead to complications - KMVT
Split Fed. Circ. Says $452M Trade Secret Case Was Untimely - Law360
US court overturns Insulet's $59 million insulin-pump trade secret verdict against EOFlow - Reuters
Insulet Corp. Stock Hits 52-Week Low at USD 141.02 Amid Decline - Markets Mojo
Insulet’s $59 Million Trade Secrets Award Voided on Appeal (1) - Bloomberg Law News
PODD Stock: What a Hold Rating Says at a $163 Target - Yahoo Finance
PODD Reiterated by RBC Capital -- Price Target Maintained at $28 - GuruFocus
Diabetes Insulin Pods Linked to 24 Serious Adverse Events Worldwide - mb.ntd.com
Insulet Corp. stock underperforms Wednesday when compared to competitors - MSN
Insulet Corp (PODD) Stock Down 5.1% -- Now Undervalued? GF Score: 82/100 - GuruFocus
Insulet Faces the Prospect of More Direct Competition From Peers - Morningstar
Insulet Corporation stock hits 52-week low at $143.95 By Investing.com - Investing.com Canada
William Blair Initiates on Insulet (PODD) With Outperform and Says the Valuation Gap Is Hard to Justify - Insider Monkey
Insulet initiates voluntary correction on Omnipod devices - BioWorld News
Diabetes device maker Insulet to webcast talk from William Blair event - Stock Titan
Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost - Reuters
Insulet recalls 7M insulin delivery pods due to safety risk - Cardiovascular Business
PODD Maintained by BTIG -- Price Target Lowered to $235 - GuruFocus
PODD and Omnipod 5: What's Driving Insulet's 2026 Growth - Yahoo Finance
Why is Insulet stock sliding today? - Investing.com
Insulet stock maintains Buy rating at Benchmark after recall - Investing.com
Why is Insulet stock sliding today? By Investing.com - Investing.com Canada
Insulet stock maintains Buy rating at Benchmark after recall By Investing.com - Investing.com Canada
Insulet Corporation stock hits 52-week low at $143.95 - Investing.com
Insulet recalls 7M patch pumps due to leak risk - Yahoo Finance
Insulet Corporation (PODD) Announces Voluntary Medical Device Co - GuruFocus
Insulet (PODD) Issues Medical Device Correction for Omnipod Prod - GuruFocus
Stocks to Watch: Zscaler, Verra Mobility, Digital Turbine, Insulet - Moomoo
Insulet stock tumbles on voluntary device recall - Investing.com
Insulet slides after updated Class I recall record for Omnipod 5 pods draws fresh attention - Quiver Quantitative
Insulet recalls 7 million Omnipod insulin pods due to leakage - Investing.com
Insulet (NASDAQ: PODD) faces Omnipod Pod correction, up to $50M 2026 cost - Stock Titan
Insulin pod safety alert: tear risk in 7M Omnipod devices - Stock Titan
Beta Bionics to launch its first insulin patch pump to compete with Insulet - Yahoo Finance
PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill
11 Best Medical Technology Stocks to Buy Right Now - Insider Monkey
Are Wall Street Analysts Bullish on Insulet Stock? - Barchart.com
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Here’s Insiders Fund’s Thesis on Insulet Corporation (PODD) - Insider Monkey
Insulet Corporation (PODD) Announces Amendments to Bylaws and An - GuruFocus
Insulet Corp (PODD) director granted 1,660 RSUs vesting in 2027 - Stock Titan
Insulet (PODD) director receives 1,660 RSU equity award vesting in 2027 - Stock Titan
Insulet (PODD) director Timothy Scannell receives 1,660-share RSU equity award - Stock Titan
Insulet (PODD) director Minogue receives 1,660 RSUs and reports trust-held shares - Stock Titan
Insulet (PODD) director awarded 1,660 RSUs in deferred stock grant - Stock Titan
Director at Insulet (NASDAQ: PODD) receives 1,660-share RSU grant - Stock Titan
Finanzdaten der Insulet Corp-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):